What is HC Wainwright’s Forecast for DWTX FY2029 Earnings?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Research analysts at HC Wainwright decreased their FY2029 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Friday, August 14th. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of $0.52 for the year, down from their previous estimate of $0.55. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ FY2030 earnings at $1.29 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Stock Up 3.9%

DWTX stock opened at $2.14 on Monday. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The stock’s 50 day moving average is $1.60 and its 200-day moving average is $2.02. The firm has a market capitalization of $71.97 million, a PE ratio of -0.24 and a beta of 1.71.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20).

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.05% of the company’s stock.

Key Stories Impacting Dogwood Therapeutics

Here are the key news stories impacting Dogwood Therapeutics this week:

• Positive Sentiment: Dogwood will host a virtual key opinion leader event on September 1 to discuss Halneuron and the treatment of chemotherapy-induced neuropathic pain. The event will feature medical, scientific and industry experts and could increase visibility around Dogwood’s non-opioid pain-treatment program. Dogwood to Host Virtual KOL Event to Discuss Halneuron for the Treatment of Chemotherapy Induced Neuropathic Pain
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $12 price target for DWTX, substantially above recent trading levels. However, the firm’s revisions suggest the valuation support is based on future pipeline potential rather than near-term profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across the projection period. FY2026 estimates fell to a loss of $0.80 per share from $0.56, while FY2027 declined to a $0.66 loss from $0.60 and FY2028 to a $0.60 loss from $0.54. Quarterly estimates for late 2026 and 2027 were also reduced, including a change in the Q4 2026 forecast from a $0.14 profit to a $0.16 loss. These revisions point to greater expected cash burn and may weigh on the stock despite the bullish rating.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.